Yikang Biological

You Missed

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Company Drug

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise